Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 81

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 81
---
 Optional Conversion Price” equal to the lesser of:

| ● | The                                       
 applicable Series E Conversion Price, and |

| ● | the         
 greater of: |

| ● | the                       
 floor price of $1.00; and |

| ● | 95%                                                                                                                                            
 of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion. |

<div align='center'>31</div>

Alternate Conversion Upon a Triggering Event. Following the occurrence and during the continuance of a Triggering Event (as defined below), each holder
may alternatively elect to convert the Series E Preferred Stock at the “Series E Alternate Triggering Event Conversion Price”
(and together with the Series E Alternate Optional Conversion Price, each an “Series E Alternate Conversion Price”) equal
to the lesser of:

| ● | The                                       
 applicable Series E Conversion Price, and |

| ● | the         
 greater of: |

| ● | the                       
 floor price of $1.00; and |

| ● | 90%                                                                                                                                            
 of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion. |

The Series E Certificate
of Designations contains standard and customary triggering events (each, a “Series E Triggering Event”), including but not
limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare
or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1 or Form S-3 pursuant
to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the
Company’s intention not to comply with a request for conversion of any Series E Preferred Stock, and (iv) bankruptcy or insolvency
of the Company.

Other Adjustments.
In connection with the Private Placement, the Company has agreed to seek stockholder approval at a special meeting of stockholders, of
the issuance of Conversion Shares at a conversion price below the Series E Conversion Price (the date of such approval, the “Series
E Stockholder Approval Date”). If the Company has not otherwise obtained such stockholder approval prior to October 31, 2025, which
is not expected to occur, then the Company shall (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC
no later than October 31, 2025, (ii